Reversing a longstanding policy, the US government said on Friday that human and other genes should not be eligible for patents. The new position could have a huge impact on medicine and on the biotechnology industry.
The new position was declared in a friend-of-the-court brief filed by the US Department of Justice late on Friday in a case involving two human genes linked to breast and ovarian cancer.
“We acknowledge that this conclusion is contrary to the longstanding practice of the Patent and Trademark Office, as well as the practice of the National Institutes of Health and other government agencies that have in the past sought and obtained patents for isolated genomic DNA,” the brief said.
It is not clear if the position in the legal brief, which appears to have been the result of discussions among various government agencies, will be put into effect by the Patent Office.
If it were, it is likely to draw protests from some biotechnology companies that say such patents are vital to the development of diagnostic tests, drugs and the emerging field of personalized medicine, in which drugs are tailored for individual patients based on their genes.
“It’s major when the United States, in a filing, reverses decades of policies on an issue that everyone has been focused on for so long,” said Edward Reines, a patent attorney who represents biotechnology companies.
The issue of gene patents has long been a controversial and emotional one. Opponents say that genes are products of nature, not inventions, and should be the common heritage of mankind. They say that locking up basic genetic information in patents actually impedes medical progress.
Proponents say genes isolated from the body are chemicals that are different from those found in the body and therefore are eligible for patents.
The Patent and Trademark Office has sided with the proponents and has issued thousands of patents on the genes of various organisms, including on an estimated 20 percent of human genes.
However, in its brief, the government said it now believed that the mere isolation of a gene, without further alteration or -manipulation, did not change its nature.
“The chemical structure of native human genes is a product of nature, and it is no less a product of nature when that structure is ‘isolated’ from its natural environment than are cotton fibers that have been separated from cotton seeds or coal that has been extracted from the earth,” the brief said.
However, the government suggested such a change would have limited impact on the biotechnology industry because man-made manipulations of DNA, like methods to create genetically modified crops or gene therapies, could still be patented.
James Evans, a professor of genetics and medicine at the University of North Carolina who headed a government advisory task force on gene patents, called the government’s brief “a bit of a landmark, kind of a line in the sand.”
He said that although gene -patents had been issued for decades, the patentability of genes had never been examined in court.
That changed when the American Civil Liberties Union and the Public Patent Foundation organized various individuals, medical researchers and societies to file a lawsuit challenging patents held by Myriad Genetics and the University of Utah Research Foundation. The patents cover two genes, BRCA1 and BRCA2, and the over US$3,000 analysis Myriad performs on the genes to see if women carry mutations that predispose them to breast and ovarian cancers.
In a surprise ruling in March, Judge Robert Sweet of the US District Court in Manhattan ruled the patents invalid. He said genes were important for the information they convey, and in that sense, an isolated gene was not really different from a gene in the body. The -government said that ruling prompted it to re-evaluate its policy.
Myriad and the University of Utah have appealed.
Saying that the questions in the case were “of great importance to the national economy, to medical science and to the public health,” the Justice Department filed an amicus brief that sided with neither party. While the government took the plaintiffs’ side on the issue of isolated DNA, it sided with Myriad on patentability of manipulated DNA.
Myriad and the plaintiffs did not comment on the government’s brief by deadline for this article.
Reines, who is with the firm of Weil Gotshal & Manges and is not involved in the main part of the Myriad case, said he thought the Patent Office opposed the new position, but was overruled by other agencies. A hint is that no lawyer from the Patent Office was listed on the brief.
Yemen’s separatist leader has vowed to keep working for an independent state in the country’s south, in his first social media post since he disappeared earlier this month after his group briefly seized swathes of territory. Aidarous al-Zubaidi’s United Arab Emirates (UAE)-backed Southern Transitional Council (STC) forces last month captured two Yemeni provinces in an offensive that was rolled back by Saudi strikes and Riyadh’s allied forces on the ground. Al-Zubaidi then disappeared after he failed to board a flight to Riyadh for talks earlier this month, with Saudi Arabia accusing him of fleeing to Abu Dhabi, while supporters insisted he was
‘SHOCK TACTIC’: The dismissal of Yang mirrors past cases such as Jang Song-thaek, Kim’s uncle, who was executed after being accused of plotting to overthrow his nephew North Korean leader Kim Jong-un has fired his vice premier, compared him to a goat and railed against “incompetent” officials, state media reported yesterday, in a rare and very public broadside against apparatchiks at the opening of a critical factory. Vice Premier Yang Sung-ho was sacked “on the spot,” the state-run Korean Central News Agency said, in a speech in which Kim attacked “irresponsible, rude and incompetent leading officials.” “Please, comrade vice premier, resign by yourself when you can do it on your own before it is too late,” Kim reportedly said. “He is ineligible for an important duty. Put simply, it was
‘TERRORIST ATTACK’: The convoy of Brigadier General Hamdi Shukri resulted in the ‘martyrdom of five of our armed forces,’ the Presidential Leadership Council said A blast targeting the convoy of a Saudi Arabian-backed armed group killed five in Yemen’s southern city of Aden and injured the commander of the government-allied unit, officials said on Wednesday. “The treacherous terrorist attack targeting the convoy of Brigadier General Hamdi Shukri, commander of the Second Giants Brigade, resulted in the martyrdom of five of our armed forces heroes and the injury of three others,” Yemen’s Saudi Arabia-backed Presidential Leadership Council said in a statement published by Yemeni news agency Saba. A security source told reporters that a car bomb on the side of the road in the Ja’awla area in
The Chinese Embassy in Manila yesterday said it has filed a diplomatic protest against a Philippine Coast Guard spokesman over a social media post that included cartoonish images of Chinese President Xi Jinping (習近平). Philippine Coast Guard spokesman Jay Tarriela and an embassy official had been trading barbs since last week over issues concerning the disputed South China Sea. The crucial waterway, which Beijing claims historic rights to despite an international ruling that its assertion has no legal basis, has been the site of repeated clashes between Chinese and Philippine vessels. Tarriela’s Facebook post on Wednesday included a photo of him giving a
RSS